Roth Capital Affirms BioLineRx (BLRX) at 'Buy' Following BL-8040 Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
Go back to Roth Capital Affirms BioLineRx (BLRX) at 'Buy' Following BL-8040 Update
May 4, 2015 11:46 AM EDT
Maxim Group analyst Jason Kolbert reiterated a Buy rating and $8 price target on BioLineRx (NASDAQ: BLRX) after the company announced they have selected the 1.5 mg/kg dose of BL-8040 to move into the expansion phase of the ongoing phase II study in Acute Myeloid Leukemia (AML).
Kolbert highlighted:
With a...
More
May 4, 2015 7:01 AM EDT
BioLineRx (NASDAQ: BLRX) announced successful completion of the dose escalation stage of its ongoing Phase 2 study of BL-8040, and commencement of the expansion stage at the optimal dose of this novel treatment for acute myeloid leukemia (AML). Top-line results from the study are anticipated in the fourth quarter of 2015.
Results of the completed dose escalation stage, in which 22 patients participated, showed that all BL-8040 tested doses, up to 1.5 mg/kg, were found to be safe and well tolerated when administered in combination with Ara-C (Cytarabine). Building upon prior... More
